Prognostic role of upregulated P300 expression in human cancers: A clinical study of synovial sarcoma and a meta‑analysis

  • Authors:
    • Zihan Liu
    • Yonglai He
    • Xiaojuan Lian
    • Hong Zou
    • Yalan Huang
    • Ning Wang
    • Jianming Hu
    • Xiaobin Cui
    • Jin Zhao
    • Wenjie Zhang
    • Wenyi Gu
    • Lijuan Pang
    • Yan Qi
  • View Affiliations

  • Published online on: August 16, 2019     https://doi.org/10.3892/etm.2019.7906
  • Pages: 3161-3171
Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )
Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )


Abstract

E1A binding protein p300 (P300) is a member of the histone acetyltransferase family of transcriptional co‑activators, which are associated with various types of cancer. Numerous studies have evaluated the diagnostic value of P300, but their results are not consistent. Therefore, a clinical study and a meta‑analysis were performed in the present study to investigate the prognostic value of P300 expression in human malignant neoplasms. Immunohistochemical (IHC) analysis was used to assess P300 expression in 43 paraffin‑embedded primary synovial sarcoma (SS) samples. For the meta‑analysis, eligible studies published until January 21, 2018 were identified by searching the PubMed, EMBASE and Web of Science databases. The IHC analysis indicated a high P300 expression rate in 33.3% (10/30) of biphasic SS (BSSs) and in 60% (6/10) of monophasic fibrous SS tissues. In BSS, the expression rate was significantly higher in the epithelial component (80.0%, 24/30) than that in the spindle‑cell component (30.0%, 9/30; P<0.05). The meta‑analysis indicated that high expression of P300 was associated with poor overall survival (OS) in digestive system malignant neoplasms (HR=1.54, 95% CI: 1.20‑2.23), as well as with poor progression‑free survival, recurrence‑free survival and disease‑free survival combined (HR=1.84, 95% CI: 1.36‑2.47). Analysis of subgroups by ethnicity demonstrated that high expression of P300 was associated with poor OS in Asians (HR=1.72, 95% CI: 1.20‑2.47) but favourable OS in Caucasians (HR=0.59, 95% CI: 0.47‑0.73). Furthermore, high expression of P300 was associated with clinical stage [Relative Risk (RR)=1.30, 95% CI: 1.07‑1.58], lymph node metastasis (RR=1.30, 95% CI: 1.03‑1.64) and depth of invasion (RR=1.31, 95% CI: 1.07‑1.60). P300 expression may therefore be a useful biomarker for predicting patient prognosis in various types of human cancer.

Related Articles

Journal Cover

October 2019
Volume 18 Issue 4

Print ISSN: 1792-0981
Online ISSN:1792-1015

Sign up for eToc alerts

Recommend to Library

Copy and paste a formatted citation
APA
Liu, Z., He, Y., Lian, X., Zou, H., Huang, Y., Wang, N. ... Qi, Y. (2019). Prognostic role of upregulated P300 expression in human cancers: A clinical study of synovial sarcoma and a meta‑analysis. Experimental and Therapeutic Medicine, 18, 3161-3171. https://doi.org/10.3892/etm.2019.7906
MLA
Liu, Z., He, Y., Lian, X., Zou, H., Huang, Y., Wang, N., Hu, J., Cui, X., Zhao, J., Zhang, W., Gu, W., Pang, L., Qi, Y."Prognostic role of upregulated P300 expression in human cancers: A clinical study of synovial sarcoma and a meta‑analysis". Experimental and Therapeutic Medicine 18.4 (2019): 3161-3171.
Chicago
Liu, Z., He, Y., Lian, X., Zou, H., Huang, Y., Wang, N., Hu, J., Cui, X., Zhao, J., Zhang, W., Gu, W., Pang, L., Qi, Y."Prognostic role of upregulated P300 expression in human cancers: A clinical study of synovial sarcoma and a meta‑analysis". Experimental and Therapeutic Medicine 18, no. 4 (2019): 3161-3171. https://doi.org/10.3892/etm.2019.7906